pharma&
https://www.pharmaand.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From pharma&
Junshi/IMPACT’s Senaparib Faces Crowded PARP Inhibitor Field
The companies said their Phase III ovarian cancer study met its primary endpoint, but the market for PARP inhibitors has come under domination by Lynparza and Zejula.
Company Information
- Industry
-
Pharmaceuticals
- OTC, Consumer
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- zr pharma& GmbH
- pharma& Schweiz GmbH
- pharmaand
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice